trimetrexate has been researched along with Carcinoma, Anaplastic in 2 studies
Trimetrexate: A nonclassical folic acid inhibitor through its inhibition of the enzyme dihydrofolate reductase. It is being tested for efficacy as an antineoplastic agent and as an antiparasitic agent against PNEUMOCYSTIS PNEUMONIA in AIDS patients. Myelosuppression is its dose-limiting toxic effect.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Twenty-two patients with previously untreated metastatic breast cancer and nineteen patients with refractory metastatic breast cancer were treated with trimetrexate (TMTX)." | 9.07 | Trimetrexate in untreated and previously treated patients with metastatic breast cancer: a Cancer and Leukemia Group B study. ( Carey, RW; Clamon, GH; Costanza, ME; Dawson, NA; Korzun, AH; Norton, L; Pollak, M; Vogelzang, NJ, 1991) |
| " We determined the cytotoxicity of methotrexate and the lipid-soluble antifolate trimetrexate to various human carcinoma cells and their doxorubicin-resistant sublines." | 7.67 | Cross-resistance to the lipid-soluble antifolate trimetrexate in human carcinoma cells with the multidrug-resistant phenotype. ( Assaraf, YG; Molina, A; Schimke, RT, 1989) |
| "Twenty-two patients with previously untreated metastatic breast cancer and nineteen patients with refractory metastatic breast cancer were treated with trimetrexate (TMTX)." | 5.07 | Trimetrexate in untreated and previously treated patients with metastatic breast cancer: a Cancer and Leukemia Group B study. ( Carey, RW; Clamon, GH; Costanza, ME; Dawson, NA; Korzun, AH; Norton, L; Pollak, M; Vogelzang, NJ, 1991) |
| " We determined the cytotoxicity of methotrexate and the lipid-soluble antifolate trimetrexate to various human carcinoma cells and their doxorubicin-resistant sublines." | 3.67 | Cross-resistance to the lipid-soluble antifolate trimetrexate in human carcinoma cells with the multidrug-resistant phenotype. ( Assaraf, YG; Molina, A; Schimke, RT, 1989) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (50.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Dawson, NA | 1 |
| Costanza, ME | 1 |
| Korzun, AH | 1 |
| Clamon, GH | 1 |
| Pollak, M | 1 |
| Vogelzang, NJ | 1 |
| Carey, RW | 1 |
| Norton, L | 1 |
| Assaraf, YG | 1 |
| Molina, A | 1 |
| Schimke, RT | 1 |
1 trial available for trimetrexate and Carcinoma, Anaplastic
| Article | Year |
|---|---|
Trimetrexate in untreated and previously treated patients with metastatic breast cancer: a Cancer and Leukemia Group B study.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; | 1991 |
1 other study available for trimetrexate and Carcinoma, Anaplastic
| Article | Year |
|---|---|
Cross-resistance to the lipid-soluble antifolate trimetrexate in human carcinoma cells with the multidrug-resistant phenotype.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Carcinoma; Cell Line; Drug Resistance; Female; Gen | 1989 |